NCT07094425
Intensive Care Unit-acquired Heart Failure in Critically Ill: the ICU-HF Study
Recruiting · Not specified · Charite University, Berlin, Germany · registry updated 2025-08-13
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Critically ill patients in intensive care units (ICUs) are exposed to a wide range of complications that can affect long-term morbidity and mortality. Not only the initial diagnosis at the time of admission may lead to complications; the ICU stay itself can also be associated with specific disease patterns. One of the most frequent complications of intensive care treatment is the loss of skeletal muscle mass. Muscle atrophy can be detected in up to 17% of all critically ill ICU patients. This is accompanied by a neuromuscular organ dysfunction collectively referred to as Intensive Care Unit Acquired Weakness (ICUAW). Milder forms of ICUAW are present in up to 40% of all ICU patients, which corresponds to approximately 1.2 million individuals per year in Germany alone. These patients face a multitude of long-term complications and have an increased mortality risk that may persist for up to five years after ICU discharge. To date, the definition of ICUAW is limited to the skeletal musculature of critically ill patients. It remains unclear whether an ICU stay also affects other muscle groups, such as the myocardium....
Inclusion
- Critically ill patients aged ≥ 18 years
- Initiation of mechanical ventilation within the first 24 hours after ICU admission
- Expected duration of ICU stay of at least 3 days
Exclusion
- Language barriers
- Expected death during ICU stay or planned transition to best supportive care
- Known allergy to electrode gel
- Ultrasound not technically feasible (e.g., due to extensive wounds, skin rash, or dressings)
- Patients with a pacemaker or similar electronic devices for whom bioelectrical impedance analysis (BIA) is contraindicated
- Patients with severe aortic valve stenosis